New research presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting explores an approach that could expand the potential of cell replacement therapy for type 1 diabetes by evaluating whether immune-engineered, allogeneic insulin-producing cells can survive and function without chronic immunosuppression.
Source: Medical Xpress
